loading page

Echinacea purpurea to treat Novel Coronavirus (2019-nCoV)
  • +3
  • R. Anandan ,
  • G. Suseendran ,
  • Noor Zaman ,
  • Sarfraz Nawaz Brohi ,
  • Balaganesh ,
  • Deepak B S
R. Anandan
Author Profile
G. Suseendran
Author Profile
Noor Zaman
Taylors University

Corresponding Author:[email protected]

Author Profile
Sarfraz Nawaz Brohi
Author Profile
Author Profile
Deepak B S
Author Profile


Novel Coronavirus (2019-nCoV) or Human Coronavirus (HCoV) could be a new coronavirus that belongs to Betacoronaviruses type Human Coronaviruses, just like the Middle-East Respiratory Syndrome (MERS) coronavirus and Severe Acute Respiratory Syndrome (SARS) coronavirus. Wuhan, the capital city of Hubei province, China recorded the initial cases of this virus in December 2019. Until 2 May 2020, 10:00 CET, near 23,8287 deaths were reported out of 3.34 million confirmed cases recorded across the world. By the tip of January 2020, China confirmed that the COVID-19 transmitted from human to human. This study aims to check a completely unique medicament called “Echinacea purpurea” against the crystal structure of 2019-nCoV Main Protease. This study presents an ideal model for Echinacea purpurea to be tested in silico against 2019-nCoV Main Protease.